Results 161 to 170 of about 1,513,840 (316)
Translational neuroimaging : tools for CNS drug discovery, development and treatment /
, 2012 Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment combines the experience of academic, clinical and industrial neuroimagers in a unique collaborative approach to provide an integrated perspective of the use of small ...
McArthur, Robert A.
core
Screening and epitope characterization of Nidogen‐2‐specific nanobodies
FEBS Open Bio, EarlyView.Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen +9 more
wiley +1 more source
FEBS Open Bio, EarlyView.This study explores the feasibility of expressing the antitumoral protein Amblyomin‐X through a suicide gene therapy approach and investigates its intracellular fate after gene delivery. Although the gene is efficiently expressed, melanoma cells rapidly degrade the Amblyomin‐X protein via proteasome activity.
Victor Dal Posolo Cinel +4 more
wiley +1 more source
, 2017 The 2017 Translational Medicine Symposium was held on Feb. 27th. The symposium addressed how clinicians\u27 ideas and research results can have an impact on patient care - if they are translated into clinical practice.
Kai Kuck, PhD
core
MiR‐513a promotes human erythroid differentiation by modulating c‐Jun
FEBS Open Bio, EarlyView.During early human erythropoiesis, miR‐513a promoted erythroid differentiation in primary human CD34+ hematopoietic stem‐progenitor cells and human TF‐1 erythroleukemic cells by indirectly decreasing c‐Jun and phospho‐c‐Jun expression, which are associated with increased GATA1 expression.
MinJung Kim +11 more
wiley +1 more source
Editorial: Experimental models of epilepsy and related comorbidities, Volume II
Frontiers in Pharmacology, 2023 Mohd Farooq Shaikh +5 more
doaj +1 more source
Journal of the American College of Cardiology, 2018 C. Michael Valentine +2 more
openaire +1 more source
Translational Medicine Symposium 2017- Speaker Biographies
, 2017 Biographies for the speakers at the Translational Medicine Symposium ...
L. Bhoite, PhD; K. Kuck, PhD; T. Petelenz, PhD; G. Prestwich, PhD; C. Coppin, MD, PhD; S. Fojtik, MA; J. Hotaling, MD, MS; J. Langell, MD, PhD; J. Langell, MD, PhD; D. Sakata, MD; P. Taylor; P. Triolo, PhD, RAC; R. Looper, PhD; S. Marty, PhD; J. Rutter, PhD; J. Schiffman; S. Sharma, MA, MBA, FACP; J. Skidmore; G. Zentner, PhD; E. Braendle, MD, PhD, CEO/President, ARUP Labs; C. Hensel, PhD; L. Jenkins; N. Kusukawa, PhD; M. Langer, JD; S. Owen, PhD; A. Ward, PhD; T. Andersen, PhD, MSW, MS, LCSW; B. Chortkoff, MD; B. Elieson, MBA; J. Facelli, PhD; J. Hurdle, MD, PhD; C. Wasden, EdD, MBA; K. Wethington, MD; M. Lehmkuhle, PhD; E. Paulsen, PhD; F. Solzbacher, PhD; C. Testa, PhD; C. Testa, PhD; J. Thompson, Director Engineering Team, Technology and Venture Commercialization, University of Utah; A. Welm, PhD; M. Yu, PhD
core
Rapid screening of staphylokinase protein variants using an unpurified cell‐free expression system
FEBS Open Bio, EarlyView.An unpurified cell‐free protein synthesis (CFPS) platform enables rapid functional screening of staphylokinase variants. Direct plasminogen‐activation assays performed in microplate format provide real‐time activity readouts, allowing rapid identification and ranking of variants with improved or reduced fibrinolytic activity without protein ...
Maria Tomková +3 more
wiley +1 more source